

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
Please do not report the images to the
Image Problem Mailbox.

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 07 June 2000 (07.06.00)	Applicant's or agent's file reference 2235787/TDO
International application No. PCT/AU99/01014	Priority date (day/month/year) 17 November 1998 (17.11.98)
International filing date (day/month/year) 17 November 1999 (17.11.99)	
Applicant CHANDLER, Howard, Milne et al	

1. The designated Office is hereby notified of its election made:

☒

in the demand filed with the International Preliminary Examining Authority on:

18 May 2000 (18.05.00)

☐

in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was☐

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer R. E. Stoffel Telephone No.: (41-22) 338.83.38
--	--

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/72, 33/53, C12Q 1/28	A1	(11) International Publication Number: WO 00/29852 (43) International Publication Date: 25 May 2000 (25.05.00)
(21) International Application Number: PCT/AU99/01014 (22) International Filing Date: 17 November 1999 (17.11.99) (30) Priority Data: PP 7134 ✓ 17 November 1998 (17.11.98) AU (71) Applicant (for all designated States except US): ENTERIX INC. [US/US]; 857 Princes Point Road, Yarmouth, ME 04096 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CHANDLER, Howard, Milne [AU/US]; 857 Princes Point Road, Yarmouth, ME 04096 (US). SINATRA, Marc [US/AU]; 21 Hull Road, Beecroft, New South Wales 2119 (AU). (74) Agents: SLATTERY, John, M. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, Victoria 3000 (AU).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: A METHOD OF DETECTING THE PRESENCE OF AN ANALYTE IN A BIOLOGICAL SAMPLE (57) Abstract <p>The present invention relates generally to a method of detecting the presence of an analyte in a biological sample. A first method for detecting blood in a biological sample involves applying a sample to a first region of a test matrix, detecting globin or haemoglobin by means of an immunological test in a second region of the test matrix and detecting haem by means of a chromogen based test in a third region of the test matrix. This method is capable of differentiating between upper and lower gastrointestinal tract bleeding and is useful for the diagnosis of gastrointestinal tract diseases, in particular, lower gastrointestinal tract diseases such as colorectal cancer. A second method disclosed involves applying a sample to a first region of a test matrix, the sample is allowed to flow to a second region where it contacts an anti-analyte immunointeractive molecule and a labelled anti-analyte immunointeractive conjugate. Any analyte-anti-analyte complex that is formed is immobilised and detected in this second region, any uncomplexed labelled anti-analyte immunointeractive conjugate is allowed to flow to a third region where it is detected.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

A METHOD OF DETECTING THE PRESENCE OF AN ANALYTE IN A BIOLOGICAL SAMPLE

FIELD OF THE INVENTION

5 The present invention relates generally to a method of detecting the presence of an analyte in a biological sample. More particularly, the present invention provides a method of detecting the presence of blood in a biological sample and still more particularly, the presence of high concentrations of blood. The method of the present invention also facilitates the differentiation of upper and lower gastrointestinal tract bleeding. The method of the present
10 invention is useful, *inter alia*, for the diagnosis of gastrointestinal tract diseases and, in particular, lower gastrointestinal tract diseases such as colorectal cancer.

BACKGROUND OF THE INVENTION

15 Bleeding into the bowel is currently the best early indicator of bowel cancer (also known as colorectal cancer). Testing for systems of bleeding into the bowel is usually achieved by screening stools for the presence of blood. This test is often referred to as faecal occult blood testing (referred to as "FOBT").

20 Chemical tests are most widely used for FOBT. These tests typically require stool to be applied to paper impregnated with the chemical reagent guaiac. When developer solution is added to the paper, a blue colour develops with a positive result. Guaiac tests have the advantage of being inexpensive and easy to perform, but are less accurate (not specific for human blood) and less sensitive than desirable. Nevertheless, several international studies
25 have shown that screening patients with these tests can save lives through the early detection of pre-cancerous and cancerous lesions. The commonly used guaiac tests detect the haem of haemoglobin, and as this is relatively resistant to breakdown in the small intestine, these tests may detect bleeding anywhere within the intestinal tract. For colorectal cancer screening this is a disadvantage as these tumours are confined to the large intestine.

- 2 -

Recently more sensitive and specific immunological tests (e.g. immunochromatographic tests) have been developed that have the potential to improve the accuracy of detecting blood in screening for colorectal cancer. These tests typically detect the globin protein of haemoglobin, a protein that does not survive passage through the upper gastrointestinal tract.

- 5 A positive immunological test therefore indicates lower gastrointestinal bleeding. In common with all immunologically based tests, however, these tests are subject to a "prozone" or "high dose hook" effect, where at high levels of analyte, the test may be inhibited to the extent that heavy bleeding may be missed.
- 10 Accordingly, there is a need to develop improved methods of detecting blood in biological samples which methods minimise the incidence of false negative results obtained due to the effects of the prozone phenomenon. In work leading up to the present invention, the inventor has developed a method of screening biological samples for the presence of blood utilising a two part testing procedure which comprises an immunological screen for the presence of the
- 15 globin component of haemoglobin performed and a non-immunological screen for the haem component of haemoglobin. Accordingly, even if the immunological detection method utilised to screen for globin produces a false negative result due to the presence of high concentrations of globin, the haem test which is not sensitive to the effects of the prozone phenomenon will nevertheless produce a positive result. The inventors have also developed
- 20 an immunological screening method which overcomes the effects of the prozone phenomenon.

SUMMARY OF THE INVENTION

- Throughout this specification and the claims which follow, unless the context requires
- 25 otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

- Accordingly, the present invention provides a method of detecting the presence of blood in
- 30 a biological sample, said method comprising the steps of:

- 3 -

- (i) applying a biological sample to a first region of a test matrix which test matrix comprises multiple regions;
- (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and
- (iii) permitting flowing of said biological sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem.

Accordingly, the present invention more particularly provides a method of detecting the presence of blood in a gastrointestinal sample, said method comprising the steps of :

15

- (i) applying a gastrointestinal sample to a first region of a test matrix which test matrix comprises multiple regions;
- (ii) permitting flowing of said gastrointestinal sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and
- (iii) permitting flowing of said gastrointestinal sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem.

20
25

According to this preferred embodiment, the present invention provides a method of detecting the presence of blood in a gastrointestinal sample, said method comprising the steps of:

30

- 4 -

- (i) applying a gastrointestinal sample to a first region of a test matrix which test matrix comprises multiple regions;
- (ii) permitting flowing of said gastrointestinal sample to a second region of said test matrix
5 wherein said sample is placed in contact with an antiglobin antibody for a time and under conditions sufficient for a globin antiglobin complex to form and detecting said globin antiglobin complex; and
- (iii) permitting flowing of said gastrointestinal sample to a third region of said test matrix
10 wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem.

Accordingly, another aspect of the present invention is directed to a method of detecting lower gastrointestinal bleeding, said method comprising the steps of:

15

- (i) applying a faecal sample to a first region of a test matrix which test matrix comprises multiple regions;
- (ii) permitting flowing of said faecal sample to a second region of said test matrix wherein
20 said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and
- (iii) permitting flowing of said faecal sample to a third region of said test matrix wherein
25 said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem;

wherein a positive haem result and a positive globin result is indicative of lower gastrointestinal tract bleeding.

30

- 5 -

Yet another aspect of the present invention is directed to a method of detecting upper gastrointestinal tract bleeding, said method comprising the steps of:

5 (i) applying a faecal sample to a first region of a test matrix which test matrix comprises multiple regions;

(ii) permitting flowing of said faecal sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and
10 detecting said globin-antiglobin complex; and

(iii) permitting flowing of said faecal sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem;
15

wherein a positive haem result and a negative globin result is indicative of upper gastrointestinal tract bleeding.

Yet another aspect of the present invention is directed to a method of diagnosing disease
20 conditions, the symptoms of which include bleeding, said method comprising the steps of:

(i) applying a biological sample to a first region of a test matrix which test matrix comprises multiple regions;

25 (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and

- 6 -

- (iii) permitting flowing of said biological sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem.

5 Preferably, the present invention is directed to a method of diagnosing colorectal cancer, said method comprising the steps of:

- (i) applying a faecal sample to a first region of a test matrix which test matrix comprises multiple regions;

10

- (ii) permitting flowing of said faecal sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and

15

- (iii) permitting flowing of said faecal sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem;

20 wherein a positive haem result and a positive globin result is indicative of colorectal cancer.

In a further aspect, the present invention provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:

- 25 (i) applying a biological sample to a first region of a test matrix, which test matrix comprising multiple regions;

- (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an anti-analyte immunointeractive molecule for a time and under conditions sufficient for an analyte-anti-analyte complex

30

- 7 -

to form, immobilising said complex and detecting said complex by contacting said analyte with an anti-analyte immunointeractive conjugate;

- 5 (iii) permitting flowing of uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is detected.

In another further aspect, the present invention provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:

- 10 (i) applying a biological sample to a first region of a test matrix, which test matrix comprises multiple regions;
- (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an anti-analyte antibody for a time and
15 under conditions sufficient for an analyte-anti-analyte complex to form, immobilising said complex and detecting said complex by contacting said analyte with an anti-analyte antibody conjugate; and
- (iii) permitting flowing uncomplexed conjugate to a third region of said test matrix wherein
20 said uncomplexed conjugate is detected.

Accordingly, the present invention more particularly provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:

- 25 (i) applying a biological sample to a first region of a test matrix, which test matrix comprises multiple regions;
- (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an anti-analyte immunointeractive
30 molecule for a time and under conditions sufficient for an analyte-anti-analyte complex

- 8 -

to form, immobilising said complex and detecting said complex by contacting said analyte with an anti-analyte immunointeractive conjugate; and

- (iii) permitting flowing uncomplexed conjugate to a third region of said test matrix wherein
5 said uncomplexed conjugate is detected;

wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).

10 In accordance with this more particular aspect of the present invention, in performing an analysis of the result obtained in step (ii) relative to the detection result in step (iii):

- (a) a strong positive detection result at both steps (ii) and (iii) is indicative of a high analyte concentration;
- 15 (b) a weaker positive detection result at step (ii) relative to a stronger positive detection of step (iii) is indicative of a low analyte concentration;
- (c) a weak positive detection result at both steps (ii) and (iii) is indicative of very high
20 analyte concentration; and
- (d) no detectable result at either steps (ii) or (iii) is indicative of extremely high analyte concentration.

25 Still more particularly, the present invention provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:

- (i) applying a biological sample to a first region of a test matrix, which test matrix comprises multiple regions;

30

- 9 -

(ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an anti-analyte immunointeractive molecule for a time and under conditions sufficient for an analyte-anti-analyte complex to form, immobilising said complex and detecting said complex by contacting said analyte with an anti-analyte immunointeractive conjugate; and

(iii) permitting flowing uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is placed in contact with said analyte, which analyte is immobilised in said third region, for a time and under conditions sufficient for an analyte-conjugate complex to form and detecting said complex;

wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).

In still another further aspect, the present invention provides a method of detecting the presence of blood in a biological sample, said method comprising the steps of:

(i) applying a biological sample to a first region of a test matrix, which test matrix comprises multiple regions;

(ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an antihaemoglobin antibody for a time and under conditions for a haemoglobin-antihaemoglobin complex to form, immobilising said complex and detecting said complex by contacting said haemoglobin with an antihaemoglobin conjugate; and

(iii) permitting flowing of uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is placed in contact with said haemoglobin, which haemoglobin is immobilised in said third region, for a time and under conditions sufficient for a haemoglobin-conjugate complex to form and detecting said complex;

- 10 -

wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).

- 11 -

DETAILED DESCRIPTION OF THE INVENTION

The present invention is predicated, in part, on the development of a blood screening method which screens for both the globin component of haemoglobin and the haem component of haemoglobin. By combining an immunological test for globin with a non-immunological test for haem, the incidence of false negative results occurring due to the prozone phenomenon are minimised. The use of a two step testing procedure directed to testing for both the haem and the globin components of haemoglobin also permits differentiation of upper gastrointestinal tract bleeding from lower gastrointestinal tract bleeding. There has also been developed an immunological based screening method which overcomes the analytically misleading test results which can be obtained when the prozone phenomenon occurs due to high analyte concentrations.

Accordingly, the present invention provides a method of detecting the presence of blood in a biological sample, said method comprising the steps of:

- (i) applying a biological sample to a first region of a test matrix which test matrix comprises first, second and third regions;
- (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and
- (iii) permitting flowing of said biological sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem.

Reference to a "chromogen" should be understood as a reference to any chromogen which reacts with oxygen to produce a colour change. Chromogens suitable for use in the present

- 12 -

invention include, but are not limited to, guaiac, tetramethyl benzidine, ortho toluidine or functional equivalents thereof. Preferably, said chromogen is guaiac.

Accordingly, the present invention more particularly provides a method of detecting the
5 presence of blood in a biological sample, said method comprising the steps of:

- (i) applying a biological sample to a first region of a test matrix which test matrix comprises first, second and third regions;
- 10 (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and
- 15 (iii) permitting flowing of said biological sample to a third region of said test matrix wherein said sample is placed in contact with guaiac or functional equivalent thereof for a time and under conditions sufficient for said guaiac to detect haem.

Reference to "biological sample" should be understood as a reference to any sample of
20 biological material derived from an animal such, but not limited to, mucus, faeces, urine, biopsy specimens and fluid which has been introduced into the body of an animal and subsequently removed such as, for example, the saline solution extracted from the lung following lung lavage or the solution retrieved from an enema wash. The biological sample which is tested according to the method of the present invention may be tested directly or may
25 require some form of treatment prior to testing. For example, a biopsy sample may require homogenisation prior to testing. Further, to the extent that the biological sample is not in liquid form, (for example it may be a solid, semi-solid or a dehydrated liquid sample) it may require the addition of a reagent, such as a buffer, to mobilise the sample. The mobilising reagent may be mixed with the biological sample prior to application of the sample to the test
30 matrix or the reagent may be applied to the sample after the sample has been applied to the test matrix. The use of a mobilising reagent is required to facilitate flowing (wicking) of the

- 13 -

sample along the test matrix. Preferably, the biological sample is a gastrointestinal sample. By "gastrointestinal sample" is meant any sample which is derived from the gastrointestinal tract. For example, faeces, mucus (for example the mucus from a rectal mucus swab), enema wash solution or a gastrointestinal tract biopsy sample.

5

The term "animal" as used herein includes a human, primate, livestock animal (e.g. sheep, pig, cow, horse, donkey), laboratory test animal (e.g. mouse, rat, rabbit, guinea pig), companion animal (e.g. dog, cat), captive wild animal (e.g. fox, kangaroo, deer), aves (e.g. chicken, geese, duck, emu, ostrich), reptile or fish.

10

Accordingly, the present invention more particularly provides a method of detecting the presence of blood in a gastrointestinal sample said method comprising the steps of :

- (i) applying a gastrointestinal sample to a first region of a test matrix which test matrix
15 comprises first, second and third regions;
- (ii) permitting flowing of said gastrointestinal sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex
20 to form and detecting said globin-antiglobin complex; and
- (iii) permitting flowing of said gastrointestinal sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem.

25

Preferably said chromogen is guaiac or functional equivalent thereof.

Reference to "test matrix" is a reference to any device which is suitable for sequentially testing a biological sample for the presence of the globin component of haemoglobin, utilising
30 a immunological test, and the haem component of haemoglobin, using a chromogen or functional equivalent thereof. In a particularly preferred embodiment, said test matrix is a

chromatographic test strip which comprises a first region for receiving a biological sample and a second region which comprises two sections. The first section of the second region is an area of immobilised antiglobin antibody coupled to colloidal gold particles which are re-suspendible by a passing liquid front while the second section of the second region is an area of immobilised antiglobin capture antibody. The third region comprises an absorbent pad impregnated with guaiac. Alternatively, the third region may comprise a strip of guaiac impregnated paper which is laminated to the second region. It should be understood that the three regions detailed in the present invention may be positioned sequentially or in some other manner, such as superimposed. For example, the first and second regions may be combined such that the sample is deliverable directly into the second region. The test matrix of the present invention may also comprise additional regions. For example, the present invention envisages the use of chromatographic strips which comprises an absorbent pad located after the third region.

Without limiting the present invention to any one theory or mode of action, according to a preferred aspect of the invention the biological sample which is applied to the first region wicks from the first region to the second region and the detection of globin and haem is then performed as a sequential two step procedure. At the second region, the globin component of any haemoglobin which is present in the sample is bound by the antiglobin antibody coupled to the colloidal gold particles. The passing biological sample front re-suspends these antibodies and both the globin-antiglobin complex and the free anti-globin antibody wick from the first section of the second region to the second section. At the second section the globin component of any haemoglobin present in the sample becomes bound to the immobilised antiglobin capture antibody while free antiglobin coupled to colloidal gold, the non-globin components of the biological sample and any excess globin which is not bound by the anti-globin antibodies of the second region continued to wick into the third region. At the third region, the haem component of any haemoglobin which has not been captured at the second region reacts with a developer solution to cause the release of oxygen, which oxygen reacts with a chromogen such as guaiac to result in a colour change.

- 15 -

In the event that a biological sample comprises high concentrations of blood, and therefore high concentrations of haemoglobin, a false negative result may be obtained at the second region of the test matrix due to the prozone phenomenon. In this event, the third region of the test matrix, which detects the haem component of haemoglobin based on the non-immunological chromogen reaction, will nevertheless produce a positive result. Accordingly, the incorporation of a non-immunological chromogen test with the immunological globin test provides a safe guard against obtaining false negative results due to the effects of the prozone phenomenon where high concentrations of blood are present in the sample.

10

The method of the present invention requires that the haemoglobin of the red blood cells is exposed prior to commencement of the test. This may be achieved by any one of a number of methods known to those skilled in the art. For example, contacting the biological sample with a red blood cell lysis solution, prior to commencement of the test, would achieve this object. It is also within the scope of this invention to cleave the haem and the globin components of the haemoglobin either before the test begins or at some point before the biological sample wicks into the third region. In this way, it would be possible to minimize the incidence of the haem component being trapped by the antiglobin capture antibodies by virtue of its attachment to the globin component.

20

Reference to "immunointeractive molecule" should be understood as a reference to any molecule comprising an antigen binding portion or a derivative of said molecule. Examples of molecules contemplated by this aspect of the present invention include, but are not limited to, monoclonal and polyclonal antibodies (including synthetic antibodies), hybrid antibodies, humanised antibodies, catalytic antibodies) and T cell antigen binding molecules. Preferably, said immunointeractive molecule is an antibody.

30

According to this preferred embodiment, the present invention provides a method of detecting the presence of blood in a gastrointestinal sample said method comprising the steps of:

- 16 -

- (i) applying a gastrointestinal sample to a first region of a test matrix which test matrix comprises first, second and third regions;
- (ii) permitting flowing of said gastrointestinal sample to a second region of said test matrix
5 wherein said sample is placed in contact with an antiglobin antibody for a time and under conditions sufficient for a globin antiglobin complex to form and detecting said globin antiglobin complex; and
- (iii) permitting flowing of said gastrointestinal sample to a third region of said test matrix
10 wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem.

More preferably, said biological sample is a faecal sample. Even more preferably, said chromogen is guaiac or functional equivalent thereof.

15

Reference to "functional equivalents" should be understood as a reference to fragments, parts, portions, mutants, homologues, mimetics from natural, synthetic or recombinant sources including fusion proteins which exhibit chromogen activity. Derivatives may be derived from insertion, deletion or substitution of amino acids. Amino acid insertional derivatives include
20 amino and/or carboxylic terminal fusions as well as intrasequence insertions of single or multiple amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterised by the removal of one or more amino acids from the sequence.
25 Substitutional amino acid variants are those in which one residue in the sequence has been removed and a different residue inserted in its place. Additions to amino acid sequences include fusions with other peptides, polypeptides or proteins.

The term "functional equivalents" as used herein should also be understood to encompass
30 molecules exhibiting any one or more of the functional activities of a chromogen, such as, for example, products obtained following natural product screening.

- 17 -

Reference to a biological sample being "placed in contact" with an immunointeractive molecule or a chromogen should be understood as a reference to any method of facilitating the interaction of any one or more components of the biological sample with the immunointeractive molecule or the chromogen such that coupling, binding or other association
5 between the one or more components of the biological sample and the immunointeractive molecule or a chemical reaction involving one or more components of the biological sample such that the chromogen colour change may occur (such as one or more components of the biological sample reacting with the developer to cause the release of oxygen which oxygen reacts with the chromogen to cause a colour change). For example the biological sample may
10 be applied to a chromatographic strip which is impregnated with the immunointeractive molecule at the second region and the chromogen at the third region. In this instance the action of the biological sample wicking up the strip to the regions of impregnation place the sample in contact with the immunointeractive molecule or the chromogen. Alternatively, the biological sample may be applied to a chromatographic strip and the immunointeractive
15 molecules or the chromogen may be added to the test strip at the time of testing such as simultaneously with the application of the biological sample or sequentially following the application of the biological sample. Also encompassed within the scope of "placed in contact" are combinations wherein one or more of the immunointeractive molecules, detection reagents, the chromogen or developer therefore are impregnated in the strip and others of
20 these reagents are added to the strip at the time of testing.

"Detecting" the formation of a globin-antiglobin complex or the chemical reaction between haem and the chromogen may be by any convenient method which will be known to those skilled in the art. In the method of the invention exemplified herein, the antiglobin antibody
25 which becomes resuspended by the wicking biological sample front is complexed with colloidal gold. As the globin-antiglobin/colloidal gold complex is trapped by the antiglobin capture antibody impregnated in the second section of the second region of the chromatography strip, the colloidal gold becomes visible as a pink band due to its increasing concentration during trapping of the complex at this point. Alternatively, the antiglobin
30 antibody may be radio-labelled or enzymatically labelled such that upon addition of a substrate a colour change is observed if globin is present. The detection of haem by a chromogen is

preferably achieved by the addition of a developer such as peroxide which reacts with haem to produce water and oxygen. The oxygen which is liberated then reacts with the chromogen to produce a colour change. For example, when guaiac reacts with oxygen a blue colour is produced. The chromogen may be incorporated into the test matrix at the third region
5 together with the developer or else the developer may be added as a liquid reagent at a later stage. If the developer is dried into the test matrix with the chromogen, then the paper will turn blue upon the arrival of aqueous haemoglobin. Alternatively, some other type of reporter molecule which detects the reactivity between the haem and the chromogen or functional equivalent thereof may be used.

10

In a preferred aspect, the present invention is used to diagnose gastrointestinal tract bleeding by analysing faecal samples for the presence of blood. Without limiting the present invention to any one theory or mode of action, the chromogen test will positively identify bleeding from any part of the gastrointestinal tract (that is, both the upper and lower regions of the tract)
15 since it detects the haem component of haemoglobin and haem is relatively resistant to breakdown in the small intestine (the upper gastrointestinal tract). The globin component of haemoglobin however, does not survive passage through the upper gastrointestinal tract. A positive globin result in a faecal sample therefore indicates that bleeding has occurred in the lower gastrointestinal tract. Accordingly, by applying a combined two step immunological
20 and non-immunological based test, it is possible to differentiate between upper and lower gastrointestinal tract bleeding wherein a positive haem result together with a negative globin result indicates upper gastrointestinal tract bleeding and a positive haem result together with a positive globin result indicates lower gastrointestinal tract bleeding. This is of particular importance, for example to the diagnosis of colorectal cancer, the symptoms of which include
25 lower gastrointestinal tract bleeding.

Accordingly, another aspect of the present invention is directed to a method of detecting lower gastrointestinal bleeding said method comprising the steps of:

- 30 (i) applying a faecal sample to a first region of a test matrix which test matrix comprises first, second and third regions;

- 19 -

- (ii) permitting flowing of said faecal sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and

5

- (iii) permitting flowing of said faecal sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem;

10 wherein a positive haem result and a positive globin result is indicative of lower gastrointestinal tract bleeding.

Preferably said chromogen is guaiac or functional equivalent thereof.

15 Yet another aspect of the present invention is directed to a method of detecting upper gastrointestinal tract bleeding said method comprising the steps of:

- (i) applying a faecal sample to a first region of a test matrix which test matrix comprises first, second and third regions;

20

- (ii) permitting flowing of said faecal sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and

25

- (iii) permitting flowing of said faecal sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem;

30 wherein a positive haem result and a negative globin result is indicative of upper gastrointestinal tract bleeding.

- 20 -

Preferably said chromogen is guaiac or functional equivalent thereof.

Yet another aspect of the present invention is directed to a method of diagnosing disease conditions, the symptoms of which include bleeding, said method comprising the steps of:

5

(i) applying a biological sample to a first region of a test matrix which test matrix comprises first, second and third regions;

10

(ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and

15

(iii) permitting flowing of said biological sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem.

Preferably, the present invention is directed to a method of diagnosing colorectal cancer said method comprising the steps of:

20

(i) apply a faecal sample to a first region of a test matrix which test matrix comprises first, second and third regions;

25

(ii) permitting flowing of said faecal sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and

30

(iii) permitting flowing of said faecal sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem;

- 21 -

wherein a positive haem result and a positive globin result is indicative of colorectal cancer.

Preferably said chromogen is guaiac or functional equivalent thereof.

5 The inventors have also surprisingly determined that by screening for the presence of unbound conjugate, in addition to screening for the analyte of interest, the effects of the prozone phenomenon can be overcome where an immunological screening technique is utilised. Without limiting the present invention to any one theory or mode of action, where an immunological test screen is utilised to detect the presence of an analyte, which method relies
10 on the capture of the subject analyte by both an immobilised immunointeractive molecule and a labelled immunointeractive molecule conjugate which ultimately provides the detection means, by analysing the level of unbound detection molecule relative to the analyte test result, the test results which often arise due to prozone effects, and which are often misleading, can be interpreted correctly.

15

Accordingly, in another aspect, the present invention provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:

- (i) applying a biological sample to a first region of a test matrix, which test matrix
20 comprising multiple regions;
- (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an anti-analyte immunointeractive molecule for a time and under conditions sufficient for an analyte-anti-analyte complex
25 to form, immobilising said complex and detecting said complex by contacting said analyte with an anti-analyte immunointeractive conjugate;
- (iii) permitting flowing of uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is detected.

30

- 22 -

It should be understood that the terms "biological sample", "test matrix", "immunointeractive molecule", "detecting" and the phrase "placed in contact" have the same meaning as previously defined. Reference to an "anti-analyte immunointeractive molecule" should be understood as a reference to any molecule which can interact with the analyte of interest to
5 form a complex. Preferably, said immunointeractive molecule is an antibody. In this regard, reference to an "anti-analyte immunointeractive conjugate" should be understood as reference to a molecule which can interact with the analyte of interest and which molecule either directly or indirectly facilitates the detection of the complexed, immobilised analyte described in step (ii), above. Preferably, the conjugate interact in an antigen specific manner with the
10 analyte of interest. Reference to "detecting" has the same meaning as hereinbefore defined. The conjugate will act "indirectly", for example, if it requires an additional step to achieve visualisation of the analyte complex. For example, where the conjugate comprises an enzymatically labelled antibody, to which a substrate must be added in order to achieve a visually detectable colour change. The conjugate acts "directly" if no additional steps are
15 required to achieve visualisation. For example, where the subject conjugate is an antibody coupled to colloidal gold, the colloidal gold will become visible as a pink band due to its increasing concentration during trapping of the conjugate.

In a preferred embodiment, the present invention provides a method of detecting the presence
20 of an analyte in a biological sample, said method comprising the steps of:

- (i) applying a biological sample to a first region of a test matrix, which test matrix comprises multiple regions;
- 25 (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an anti-analyte antibody for a time and under conditions sufficient for an analyte-anti-analyte complex to form, immobilising said complex and detecting said complex by contacting said analyte with an anti-analyte antibody conjugate; and

- 23 -

- (iii) permitting flowing uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is detected.

Detection of the uncomplexed immunoglobulin conjugate may be performed by any suitable
5 technique. For example, the conjugate may be detected in a non-specific manner such as via
an immobilised anti-immunoglobulin antibody which captures the subject conjugate.
Alternatively, it may be detected in a specific manner such as via a region of immobilised
antigen to which the antibody conjugate is specifically directed. In a preferred embodiment,
the conjugate is detected in an antigen specific manner thereby facilitating the optional
10 inclusion of a control test to confirm that wicking of the conjugate along the test matrix
actually occurs. A typical control test may therefore take the form of a region of immobilised
anti-immunoglobulin antibody which captures a small portion of the immunoglobulin conjugate.
In accordance with this embodiment, detection of the uncomplexed conjugate is achieved in
an immunologically specific manner via a region of immobilised antigen to which the
15 conjugate is specifically directed. This antigen is preferably the analyte of interest.

The steps of immobilising the analyte of interest and detecting said analyte may be performed
in any suitable manner. For example, the steps may be performed sequentially or
simultaneously. In a preferred aspect, the biological sample is applied to an application
20 region of a chromatographic strip, where it is placed in contact with a colloidal gold labelled
anti-analyte antibody conjugate. Following complexation of the conjugate with any analyte
present in the biological sample, the sample, together with any unbound conjugate, is allowed
to wick along the chromatographic strip to a second region where it contacts an immobilised
anti-analyte antibody. Any analyte present in the sample will complex with the immobilised
25 anti-analyte antibody. Where the analyte has previously complexed with the colloidal gold
conjugate, it will become evident as a pink band which darkens as the labelled antibody is
immobilised in the test region and its concentration increases. Any excess unbound conjugate
together with the unbound biological sample components will continue to wick into a third
region of the test matrix. The third region of the test matrix comprises immobilised analyte
30 which will complex any unbound anti-analyte conjugate.

- 24 -

By comparing the relative intensities of the analyte test results of the second region and the conjugate test results of the third region, it is possible to determine, with greater certainty than has previously been available, whether the analyte of interest is present in the subject biological sample. Due to the fact that this technique facilitates the correct interpretation of whether or not the analyte results of region two have been subject to the occurrence of the prozone phenomenon, the results also provide a general indication of the concentration of analyte present in the sample. For example, where the analyte of interest is haemoglobin, a biological sample which does not contain any haemoglobin will produce a negative result in the second region and a strongly positive result in the third region where all the available conjugate will ultimately become complexed with the immobilised haemoglobin. Where low haemoglobin concentrations are present in a test sample, a weak positive result would be expected in the second region while a strong signal would be detected in the third region since the low level of haemoglobin initially present in the sample would have complexed only a small proportion of the total conjugate available for testing. Where high haemoglobin concentrations are present, the prozone phenomenon will result in a weak signal being detected in the second region together with a weak signal present in the third region where severely depleted conjugate concentration would become immobilised. Where extremely high haemoglobin concentrations are present it would be expected that no signal is detected in either the second or third regions due to the lack of free unbound conjugate and the nevertheless excessive concentrations of unbound haemoglobin.

In this regard, it should be understood that reference to "weak" or "strong" detection results which are obtained via steps (ii) and (iii) are characterised as being of a weak or strong nature when analysed relative to one another. These results are not necessarily analysed relative to an objective standard, although such an objective analysis is in no way excluded from the scope of the present invention. The detection result may be assessed by any suitable means. For example, where the conjugate is designed to render a colour change, the occurrence of a colour change may be assessed either by eye or via instrumental reading. Depending on the concentration of conjugate which has been immobilised this colour change may be of a faint or intense nature, corresponding to a weak or strong result, respectively. Once the detection results have been visualised, analysis of the intensity of result obtained from step (ii) relative

- 25 -

to the result obtained at step (iii) will be indicative of the concentration of analyte which is present in the biological sample in terms of whether the analyte is present in low, high or very high levels.

5 Accordingly, the present invention more particularly provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:

(i) applying a biological sample to a first region of a test matrix, which test matrix comprises multiple regions;

10

(ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an anti-analyte immunointeractive molecule for a time and under conditions sufficient for an analyte-anti-analyte complex to form, immobilising said complex and detecting said complex by contacting said

15

(iii) permitting flowing uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is detected;

20 wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).

In accordance with this more particular aspect of the present invention, in performing an analysis of the result obtained in step (ii) relative to the detection result in step (iii):

25

(a) a strong positive detection result at both steps (ii) and (iii) is indicative of a high analyte concentration;

(b) a weaker positive detection result at step (ii) relative to a stronger positive detection of step (iii) is indicative of a low analyte concentration;

30

- 26 -

- (c) a weak positive detection result at both steps (ii) and (iii) is indicative of very high analyte concentration; and
- (d) no detectable result at either steps (ii) or (iii) is indicative of extremely high analyte concentration.

It should be understood that where the detection results obtained at step (ii) and step (iii) are equivalent, assessment of whether this result is strongly positive or weakly positive may be analysed relative to an objective standard or can be assessed by the person skilled in the art in a subjective manner based on the technical knowledge and experience which such a person would possess. Where the detection results are analysed by instrumentation it may be possible to precisely quantitate the concentration of analyte present in the sample. Where the detection results are analysed by less precise means (such as by the human eye) although a precise quantitative value is not obtained, in addition to overcoming the misleading results which are caused by the prozone phenomenon, the results obtained will nevertheless broadly indicate whether the analyte is present in low, high or very high levels. This level of information can be, nevertheless, of great value. For example, where a patient presents with symptoms of bowel cancer, obtaining a broad indication of whether the patient is bleeding mildly or severely is of assistance in planning further testing and/or treatment.

Still more particularly, the present invention provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:

- (i) applying a biological sample to a first region of a test matrix, which test matrix comprises multiple regions;
- (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an anti-analyte immunointeractive molecule for a time and under conditions sufficient for an analyte-anti-analyte complex to form, immobilising said complex and detecting said complex by contacting said analyte with an anti-analyte immunointeractive conjugate; and

- 27 -

- (iii) permitting flowing uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is placed in contact with said analyte, which analyte is immobilised in said third region, for a time and under conditions sufficient for an analyte-conjugate complex to form and detecting said complex;

5

wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).

In a preferred embodiment, the present invention provides a method of detecting the presence
10 of blood in a biological sample, said method comprising the steps of:

- (i) applying a biological sample to a first region of a test matrix, which test matrix comprises multiple regions;
- 15 (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an antihaemoglobin antibody for a time and under conditions for a haemoglobin-antihaemoglobin complex to form, immobilising said complex and detecting said complex by contacting said haemoglobin with an antihaemoglobin conjugate; and

20

- (iii) permitting flowing of uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is placed in contact with said haemoglobin, which haemoglobin is immobilised in said third region, for a time and under conditions sufficient for a haemoglobin-conjugate complex to form, and detecting said
25 complex;

wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).

30 A test directed to detecting unbound conjugate can be incorporated as an additional component of any new or existing test matrix format. For example, the test format described in

- 28 -

accordance with this aspect of the present invention may optionally comprise a fourth test matrix region which is impregnated with a chromogen such as guiac for the purpose of additionally and simultaneously detecting haem. This is of particular relevance where it is necessary to differentiate upper from lower gastrointestinal tract bleeding as hereinbefore
5 described.

Further features of the present invention are more fully described in the following non-limiting Examples. It is to be understood, however, that the following description is included solely for the purpose of exemplifying the present invention.

10

EXAMPLE 1

CHROMATOGRAPHIC TEST STRIP

Immunochromatographic tests typically use dried immunological reagents on a test strip.

5 Liquid sample applied to the origin of the test strip flows through the various regions so that with a positive result, a coloured line develops in the upper region of the test strip. The reagents and sample then flow into an absorbent matrix at the top of the test strip. This absorbent is most commonly an absorbent paper, such as blotting paper.

10 It has now been found that this absorbent paper may be impregnated with guaiac, so that addition of developer solution to the absorbent at the conclusion of the immunological test can enable:

(a) Detection of high levels of blood that may have caused inhibition of the immunological
15 test.

(b) Detection of lower gastrointestinal bleeding.

Alternatively, a strip of guaiac impregnated paper may be inserted at the upper region of the
20 test strip, between the immunological detection zone and the absorbent.

Figure 1 depicts a test matrix suitable for use according to the method of the present invention. The origin and the first section of the second region, which is impregnated with labelled antibody (for example, antiglobin antibody coupled to colloidal gold particles), are
25 made of the same material, which material is a conductive paper (Ahlstrom 1281). The capture antibody which is immobilised in the second section of the second region which region is made of Millipore nitrocellulose. Typically, a functional control line is also included in this region. The chromogen may be impregnated directly in the third region (the absorbent sink) or impregnated in a paper bridge between the second and third regions.

- 30 -

EXAMPLE 2

DETECTING HIGH CONCENTRATIONS OF BLOOD

Blood was diluted 1:100, 1:1000 and 1:10,000 in immunological test buffer. This buffer
 5 caused lysis of the red blood cells, so that the haemoglobin was liberated into solution. The
 diluted blood samples were added to wells of a microtitre plate. Three negative control wells
 were included, each containing buffer alone.

Immunological test strips (Enterix OBT) were modified so that the absorbent paper at the top
 10 of the strip was overlaid, in liquid conductive contact, with guaiac paper taken from a guaiac
 test (Hemoccult Sensa, SmithKline Diagnostics Inc., USA). The modified test strips were
 added to the microwells and yielded the following results:

		Blood Dilution			
15	Result	1:100	1:1000	1:10,000	Buffer
	Immunological	Very weak positive (prozone)	Positive	Strong positive	Negative (x3)
	Guaiac	Very strong positive	Positive	Borderline positive	Negative (x3)

20

EXAMPLE 3

EXPERIMENTAL DEMONSTRATION OF THE USE OF A THIRD (ANTIGEN) LINE IN AN IMMUNOCHROMATOGRAPHIC ASSAY FOR HUMAN HAEMOGLOBIN (Hb)

25 The purpose of the third line was to enable distinction between low signal strength due to
 prozone (high Hb concentration) from that due to low Hb concentration.

- 31 -

Preparation of test strips with a third (Hb) line

Blood was centrifuged to separate the red cells, which were then washed once with phosphate buffered saline (PBS) to remove remaining serum components. The red cells were then lysed by diluting them 1/10 with distilled water. The lysed cells were used as the source of Hb for a third line, added downstream from the Capture (anti-human Hb) and Control (anti-goat antibody) line of immunochromatographic test strips (Agen, Brisbane, Australia, Product EN12401-021 for detection of human Hb). These test strips use as the disclosing reagent a conjugate of goat anti-human Hb conjugated to colloidal gold.

10 The third line was dried to immobilise the Hb on the test strip.

Testing of the test strips

Whole blood was diluted

15

- (a) 1/100 in water = High Hb concentration
- (b) 1/20,000 - low Hb concentration

When these two Hb concentrations were tested with the test strips, the results (recorded as visible signal strength) were as shown:

	<u>(a) High Hb</u>	<u>(b) Low Hb</u>
<u>Line 1</u> = Capture line (anti-(Hb))	Weak	Weak
25 <u>Line 2</u> = Control line (anti-goat)	Strong	Strong
<u>Line 3</u> = Hb	Weak	Strong

30 Conclusion: The inclusion of the third line allowed differentiation between weak detection (capture) signals caused by high and low antigen (Hb) concentrations.

- 32 -

EXAMPLE 4**COMBINATION OF THE ANTIGEN REGION IMMUNOLOGICAL SCREEN FOR UNCOMPLEXED CONJUGATE AND A NON-IMMUNOLOGICAL SCREEN**

5 If the features disclosed in both Examples 1 and 2 are combined, the following detection zones appear along the test strip:

Line 1	=	capture Ab (anti-Hb)
Line 2	=	control Ab (anti-goat Ab)
10 Line 3	=	analyte (Hb)
Line/zone 4	=	Guaiaac (or similar) for detection of haem.

These would then allow distinction to be made between the following conditions:

15 <u>Condition</u>	<u>Line 1</u> (anti-Hb)	<u>Line 2</u> anti-conjugate)	<u>Line 3</u> (Hb)	<u>Line 4</u> (Guaiaac)
<u>No blood</u>	-	+	+	-
20 <u>Blood</u>				
1. Upper GI	-	+	+	+
2. Lower GI				
25 (a) lower [Hb]	+	+	+	+ (+/-)
(b) V. high [Hb]	-	+	-	+

30

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this
 35 specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

CLAIMS:

1. A method of detecting the presence of blood in a biological sample, said method comprising the steps of:
 - (i) applying a biological sample to a first region of a test matrix which test matrix comprises multiple regions;
 - (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and
 - (iii) permitting flowing of said biological sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem.
2. The method according to claim 1 wherein said chromogen is guaiac, tetramethyl benzidine or ortho toluidine.
3. The method according to claim 2 wherein said chromogen is guaiac.
4. The method according to claim 1 to 3 wherein said test matrix is a chromatographic strip.
5. The method according to claim 4 wherein said immunointeractive molecule is an antibody.

- 34 -

6. The method according to any one of claims 1-5 wherein said biological sample is a gastrointestinal sample.
7. The method according to claim 6 wherein said gastrointestinal sample is a faecal sample.
8. A method of detecting lower gastrointestinal bleeding said method comprising the steps of:
 - (i) applying a gastrointestinal sample to a first region of a test matrix which test matrix comprises multiple regions;
 - (ii) permitting flowing of said sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and
 - (iii) permitting flowing of said sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem;

wherein a positive haem result and a positive globin result is indicative of lower gastrointestinal tract bleeding.

9. The method according to claim 8 wherein said chromogen is guaiac, tetramethyl benzidine or ortho toluidine.
10. The method according to claim 9 wherein said chromogen is guaiac.

- 35 -

11. The method according to claim 8 to 10 wherein said test matrix is a chromatographic strip.
12. The method according to claim 11 wherein said immunointeractive molecule is an antibody.
13. The method according to any one of claims 8-12 wherein said gastrointestinal sample is a faecal sample.
14. A method of detecting upper gastrointestinal tract bleeding said method comprising the steps of:
 - (i) applying a gastrointestinal sample to a first region of a test matrix which test matrix comprises multiple regions;
 - (ii) permitting flowing of said sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detecting said globin-antiglobin complex; and
 - (iii) permitting flowing of said sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem;

wherein a positive haem result and a positive globin result is indicative of lower gastrointestinal tract bleeding.

15. The method according to claim 14 wherein said chromogen is guaiac, tetramethyl benzidine or ortho toluidine.
16. The method according to claim 15 wherein said chromogen is guaiac.

- 36 -

17. The method according to claim 14 to 16 wherein said test matrix is a chromatographic strip.
18. The method according to claim 17 wherein said immunointeractive molecule is an antibody.
19. The method according to any one of claims 14-18 wherein said gastrointestinal sample is a faecal sample.
20. A method of diagnosing disease conditions, the symptoms of which include bleeding, said method comprising the steps of:
 - (i) applying a biological sample to a first region of a test matrix which test matrix comprises multiple regions;
 - (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an antiglobin immunointeractive molecule for a time and under conditions sufficient for a globin-antiglobin complex to form and detection said globin-antiglobin complex; and
 - (iii) permitting flowing of said biological sample to a third region of said test matrix wherein said sample is placed in contact with a chromogen or functional equivalent thereof for a time and under conditions sufficient for said chromogen to detect haem.
21. The method according to claim 20 wherein said chromogen is guaiac, tetramethyl benzidine or ortho toluidine.
22. The method according to claim 21 wherein said chromogen is guaiac.

- 37 -

23. The method according to claim 20 to 22 wherein said test matrix is a chromatographic strip.
24. The method according to claim 23 wherein said immunointeractive molecule is an antibody.
25. The method according to any one of claims 20-24 wherein said disease condition is colorectal cancer and said biological sample is a gastrointestinal sample.
26. The method according to claim 25 wherein said gastrointestinal sample is a faecal sample
27. A method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:
 - (i) applying a biological sample to a first region of a test matrix, which test matrix comprising multiple regions;
 - (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an anti-analyte immunointeractive molecule for a time and under conditions sufficient for an analyte-anti-analyte complex to form, immobilising said complex and detecting said complex by contacting said analyte with an anti-analyte immunointeractive conjugate;
 - (iii) permitting flowing of uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is detected.
28. A method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:

- 38 -


- (i) applying a biological sample to a first region of a test matrix, which test matrix comprises multiple regions;
 - (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an anti-analyte immunoreactive molecule for a time and under conditions sufficient for an analyte-anti-analyte complex to form, immobilising said complex and detecting said complex by contacting said analyte with an anti-analyte immunointeractive conjugate; and
 - (iii) permitting flowing of uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is placed in contact with said analyte, which analyte is immobilised in said third region, for a time and under conditions for analyte-conjugate complex to form and detecting said complex.
29. The method according to claim 27 or 28 wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).
30. The method according to claim 29 wherein:
- (a) a strong positive detection result at both steps (ii) and (iii) is indicative of a high analyte concentration;
 - (b) a weaker positive detection result at step (ii) relative to a stronger positive detection of step (iii) is indicative of a low analyte concentration;
 - (c) a weak positive detection result at both steps (ii) and (iii) is indicative of very high analyte concentration; and
 - (d) no detectable result at either steps (ii) or (iii) is indicative of extremely high analyte concentration.
31. The method according to any one of claims 27-30 wherein said immunointeractive molecule is an antibody.

32. The method according to any one of claims 27-31 wherein said analyte is blood.
33. The method according to claim 32 wherein said biological sample is a gastrointestinal sample.
34. The method according to claim 33 wherein said gastrointestinal sample is a faecal sample.
35. A method of detecting the presence of blood in a biological sample, said method comprising the steps of:
 - (i) applying the biological sample to a first region of a test matrix, which test matrix comprises multiple regions;
 - (ii) permitting flowing of said biological sample to a second region of said test matrix wherein said sample is placed in contact with an anti-haemoglobin immunointeractive molecule for a time and under conditions sufficient for a haemoglobin-anti-haemoglobin complex to form and detecting said complex by contacting said haemoglobin with an anti-haemoglobin immunointeractive conjugate;
 - (ii) permitting flowing of said biological sample and said uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is placed in contact with said haemoglobin, which haemoglobin is immobilised in said third region, for a time and under conditions for a haemoglobin-conjugate complex to form and detecting said complex; and
 - (iv) permitting flowing of said biological sample to a fourth region of said test matrix wherein said sample is placed in contact with a chromagen or functional equivalent thereof for a time and under conditions sufficient for said chromagen to detect haem.

- 40 -

36. The method according to claim 35 wherein said biological sample is a gastrointestinal sample.
37. The method according to claim 36 wherein said gastrointestinal sample is a faecal sample.
38. The method according to any one of claims 35-37 wherein said immunointeractive molecule is an antibody and said chromogen is guaiac.
39. The method according to any one of claims 35-38 wherein the detection result of step (ii) is analysed relative to the detection result of step (iii).

1/1



Substitute Sheet
(Rule 26) RO/AU

Figure 1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/01014

A. CLASSIFICATION OF SUBJECT MATTER																						
Int Cl ⁶ : G01N 33/72, 33/53; C12Q 1/28																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols) IPC Int Cl ⁶ G01N 33/53, 33/72; C12Q 1/28																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Derwent (WPAT and JAPIO) and Medline																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
P, X	Am. J. Gastroenterol. (1999) February, 94(2), 344-350, <i>Detection of upper gastrointestinal blood with fecal occult blood tests</i> , Rockey D. C., Auslander A., Greenberg P. D. (see entire document, in particular page 344 and page 350 column 1)	1-3, 5-10, 1216, 18-22, 24-26																				
X	N. Engl. J. Med., (1996), 334(3), 155-159, <i>A comparison of fecal occult-blood tests for colorectal-cancer screening</i> , Allison J. E. et al. (see entire document)	1-7, 20-26																				
X	Derwent Abstract Accession No. 92-134663/17, Class B04 D16, HU 58917-T (Otto S) 30 March 1992. (see entire abstract)	1-7, 20-26																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex																						
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier application or patent but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 23 February 2000		Date of mailing of the international search report 01 MAR 2000																				
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer NORMAN BLOM Telephone No.: (02) 6283 2238																				

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/01014

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	European Journal of Surgical Oncology, (1989), 15(5), 446-448, <i>An evaluation of Fecatwin/Feca ELA; a faecal occult blood test for detecting colonic neoplasia</i> , Pye G. et al. (see entire document)	1-7, 20-26
X, Y	AU 84188/82 (541099) B (F. Hoffmann-La Roche and Co. Aktiengesellschaft) 20 January 1983 (see entire document, in particular page 4 lines 1-3)	1-7, 20-26 8-19
Y	Clinical Chemistry, (1988), 34(9), 1763-1776, <i>Rapid immunochemical detection of fecal occult blood by use of a latex-agglutination test</i> , Vaananen P. and Tenhunen R. (see entire document, in particular pages 1763 and 1766)	8-19
X	EP 465266 A (Sangstat Medical Corporation) 8 January 1992 (see entire document, in particular page 3 lines 22-59 and the claims)	27-29, 31
X, Y	WO 98/33069 A (Smithkline Diagnostics, Inc.) 30 July 1998 (see entire document, in particular page 1 line 18, page 3 lines 4-7, page 5 lines 14-16, page 17 lines 30-33, page 25 lines 31-34, claims 6-7 etc.)	27-29, 31-34
X, Y	AU 23725/97 A (Bayer Corporation) 4 December 1997 (see entire document, in particular page 5 line 23-page 6 line 4 and claim 11)	27-29, 31
Y	WO 91/12528 A (Hygeia Sciences, Inc.) 22 August 1991 (see page 4 line 16 to page 5 line 16)	27-29, 31
X	EP 724157 A (Bayer Corporation) 31 July 1996 (see entire document, in particular columns 2 and 3, claim 3 and example II)	27-29, 31
X	WO 97/35205 A (Serex, Inc.) 25 September 1997 (see entire document, in particular page 4 lines 5-20, page 6, page 13 lines 7-28)	27-31
P, X	AU 77440/98 A (Bayer Corporation) 4 February 1999 (see entire document, in particular see claim 11, page 21 lines 6-11)	27-29, 31-32

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/01014

Box 1 Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

This international application was found to possess two separate inventions for the reasons given below:

- (i) Claims 1-26 relate to the first invention and
 - (ii) Claims 27-34 relate to the second invention.
- (see extra sheets for a full explanation)

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

Box II

Explanation regarding finding of multiple inventions

Claims 1-26 are directed to a method of detecting the presence of blood in a biological sample which entails the following steps (i) applying a biological sample to a first region of a test matrix, (ii) permitting flow of the biological sample to a second region of the test matrix where it comes in contact with an **antiglobin immunointeractive molecule** (or antibody) which forms a globin-antiglobin complex with any globin present in the sample, and detecting this complex and (iii) permitting flow of the biological sample to a third region of the test matrix where the sample comes in contact with a **chromogen** which detects the presence of **haem**. It is to be noted that this method involves detecting the presence of **two distinct analytes** in the biological sample, each in a separate region of the test matrix. The detection of one of these two analytes involves an **immunoassay** and the detection of the second analyte is by means of a **chemical (chromogen) based assay**.

Claims 27-34 are directed to a method of detecting the presence of an analyte in a biological sample involving (i) applying the sample to a first region of a test matrix, (ii) allowing the sample to flow to a second region of the test matrix where it is contacted with an **anti-analyte immunointeractive molecule**, allowing any analyte-anti-analyte complex to form, immobilising the complex and detecting this complex by contacting it with an **anti-analyte immunointeractive conjugate** and (iii) allowing any uncomplexed conjugate to flow through to a third region of the test matrix where the uncomplexed conjugate is detected. This method involves the detection of a **single analyte** in the sample by means of an immunoassay in the second region of the test matrix, (the first region being the sample application region). The method also involves the detection of any uncomplexed anti-analyte immunointeractive conjugate in a further region of the test matrix. This uncomplexed conjugate which is detected in the third region is a **reagent** used for detecting the analyte in the second region and is not a second analyte present in the original biological sample. It is to be noted that the only methods of detecting the uncomplexed conjugate disclosed in the specification are immunoassay, and hence this method involves two immunoassays, one at each of the second and third regions.

The features common to the two groups of claims are :- (i) applying a biological sample to a first region of a test matrix, (ii) allowing the sample to flow to a second region of the test matrix where it is contacted with an anti-analyte-immunointeractive molecule, allowing any analyte present to form an analyte-anti-analyte immunointeractive complex, immobilising the complex and detecting this complex by contacting it with an anti-analyte-immunointeractive conjugate. These steps amount to nothing more than the **standard steps involved in a typical sandwich immunoassay which are very well known in the art**, examples of which are WO 96/28715, US 4960691, US 4943522 to name but a few.

The requirement of unity of invention (Rule 13.1) is fulfilled only when there is a technical relationship among those inventions involving one or more of the **same or corresponding special technical features**. The expression **special technical features** means those technical features that define a contribution which each of the claimed inventions makes over the prior art. As the method steps involving addition of a sample to a first region and allowing the sample to flow to a second region where the presence of an analyte is detected by means of an anti-analyte immunointeractive molecule amount to nothing more than a standard sandwich immunoassay one has to look to the use of a third region of the test matrix to determine any "special technical feature". The third region of the test matrix of claims 1-26 is used to detect the presence of haem (heme) using a chromogen base assay. The use of a chromogen to detect the presence of haem on a test strip is well known in the prior art and forms the basis of the currently available Hemoccult II® and HemoccultSENSA® guaiac-based tests. Likewise immunochemical tests for haemoglobin are also well known in the prior art, examples of which are HemeSelect® and HemoQuant®. The "special technical features" of claim 1-26 thus reside in the use of a **combination** of an immunoassay for globin and a chromogen based test for haem, for the detection of blood on a **single test matrix**, this being because both a chromogen based test for haem and an immunoassay for haemoglobin are both well known in the prior art, as mentioned above.

(continued)

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 99/01014

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No:II

The "special technical features" of claims 27-34 relate to the detection of uncomplexed anti-analyte immunointeractive conjugate in a further separate region of a standard sandwich-type immunoassay.

These two inventions are not so linked as to form a single general inventive concept. There is no technical relationship among these two inventions involving one or more of the same or corresponding special technical features.

Further support for the above assertion of lack of unity of invention comes from the fact that a search conducted to establish the novelty and /or inventiveness of the invention defined by claims 1-26 will not establish the novelty and inventiveness of claims 27-34 and *vice versa*.

Additional evidence that the above two groups of claims define separate inventions and that one is not merely a broader form of the other can be found in the description, in particular example 4 (page 32) from which the following results have been extracted:-

For the invention defined by claim 1-26 (test involving capture Ab (anti-Hb) and Guaiac or similar chromogen for the detection of haem)

<u>Condition</u>	<u>Line 1</u> (anti-Hb)	<u>Line 4</u> (Guaiac)
no blood	-	-
lowerGI		
v.high[Hb]	-	+

For the invention defined by claims 27-34 (test involving capture Ab (anti-Hb) and anti-conjugate (Hb))

<u>Condition</u>	<u>Line 1</u> (anti-Hb)	<u>Line 3</u> (Hb)
no blood	-	+
lower GI		
v.high[Hb]	-	-

From these results it can be clearly seen that the two inventions measure quite different species and hence give quite different results i.e. one invention is not merely a broader form of the other invention.

Claims 35-39 are considered to possess unity of invention with each of the above two groups of claims.


INTERNATIONAL SEARCH REPORT **Information on patent family members**

International application No.
PCT/AU 99/01014

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.


Patent Document Cited in Search Report				Patent Family Member			
AU	84188/82	CA	1212024	DK	3172/82	EP	70366
		ES	513992	ES	8307899	FI	821822
		JP	58023796	NO	822458	US	4683197
HU	58917	NONE					
EP	465266	JP	6317595	US	5158869		
WO	98/33069	AU	55960/98	US	5879951		
AU	77440/98	EP	895084	JP	11083856		
WO	97/35205	AU	25531/97	CA	2249303	EP	888552
EP	724157	AU	42226/96	CA	2166913	CN	1146557
		EP	724157	JP	8240591	US	5569608
		ZA	9600357				
WO	91/12528	AU	74458/91	CA	2073504	EP	514489
		US	5141850				
AU	23725/97	CA	2198948	JP	10048212		
END OF ANNEX							

TENT COOPERATION TREATY
PCT
INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)



Applicant's or agent's file reference 2235787/TDO	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International Application No. PCT/AU99/01014	International Filing Date (day/month/year) 17 November 1999	Priority Date (day/month/year) 17 November 1998
International Patent Classification (IPC) or national classification and IPC Int. Cl. ⁷ G01N 33/72, 33/53; C12Q 1/28		
Applicant ENTERIX INC. <i>et al.</i>		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2.	This REPORT consists of a total of 10 sheets, including this cover sheet. <input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of sheet(s).
3.	This report contains indications relating to the following items: I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input checked="" type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input checked="" type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input checked="" type="checkbox"/> Certain observations on the international application

Date of submission of the demand 18 May 2000	Date of completion of the report 26 February 2001
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer  NORMAN BLOM Telephone No. (02) 6283 2238

I. Basis of the report

1. With regard to the elements of the international application:*
- ☒ the international application as originally filed.
- ☐ the description, pages , as originally filed,
 pages , filed with the demand,
 pages , received on with the letter of
- ☐ the claims, pages , as originally filed,
 pages , as amended (together with any statement) under Article 19,
 pages , filed with the demand,
 pages , received on with the letter of
- ☐ the drawings, pages , as originally filed,
 pages , filed with the demand,
 pages , received on with the letter of
- ☐ the sequence listing part of the description:
 pages , as originally filed
 pages , filed with the demand
 pages , received on with the letter of
2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language which is:
- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).
3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:
- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished
4. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.
5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
- ☐ paid additional fees.
- ☐ paid additional fees under protest.
- ☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- ☐ complied with.
- ☒ not complied with for the following reasons:

This international application was found to possess two separate inventions for the following reasons;

- (i) Claims 1-26 relate to the first invention and
(ii) Claims 27-34 relate to the second invention.

Claims 1-26 are directed to a method of detecting the presence of blood in a biological sample which entails the following steps (i) applying a biological sample to a first region of a test matrix, (ii) permitting flow of the biological sample to a second region of the test matrix where it comes in contact with an **antiglobin immunointeractive molecule** (or antibody) which forms a globin-antiglobin complex with any globin present in the sample, and detecting this complex and (iii) permitting flow of the biological sample to a third region of the test matrix where the sample comes in contact with a **chromogen** which detects the presence of **haem**. It is to be noted that this method involves detecting the presence of **two distinct analytes** in the biological sample, each in a separate region of the test matrix. The detection of the first of these two analytes involves an **immunoassay** and the detection of the second analyte involves a **chemical (chromogen) based assay**.

Claims 27-34 are directed to a method of detecting the presence of an analyte in a biological sample involving (i) applying the sample to a first region of a test matrix, (ii) allowing the sample to flow to a second region of the test matrix where it is contacted with an **anti-analyte immunointeractive molecule**, allowing any analyte-anti-analyte complex to form, immobilising the complex and detecting this complex by contacting it with an **anti-analyte immunointeractive conjugate** and (iii) allowing any uncomplexed **conjugate** to flow through to a third region of the test matrix where the uncomplexed conjugate is detected. This method involves the detection of a **single analyte** in the sample by means of an immunoassay in the second region of the test matrix, (the first region being the sample application region). The method also involves the detection of any uncomplexed anti-analyte immunointeractive conjugate in a further region of the test matrix. This uncomplexed conjugate which is detected in the third region is a **reagent** used for detecting the analyte in the second region and is not a second analyte present in the original biological sample.

(continued)

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- ☒ all parts.
- ☐ the parts relating to claims Nos.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims 35-39	YES
	Claims 1-34	NO
Inventive step (IS)	Claims 35-39	YES
	Claims 1-34	NO
Industrial applicability (IA)	Claims 1-39	YES
	Claims none	NO

2. Citations and explanations (Rule 70.7)

Novelty (N) and Inventive Step (IS): Claims 1-34

The New England Journal of Medicine (1996), 334 (3), 155-159, teaches that a combination of Hemoccult II Sensa and HemeSelect tests has the highest positive predictive value and the highest specificity for carcinoma (compared with the individual tests using Hemoccult II, HemeSelect or Hemoccult II Sensa). Disclosed is a specimen card containing three faecal occult-blood tests (Hemoccult II, Hemoccult II Sensa and HemeSelect). HemeSelect is based on an antigen-antibody agglutination reaction involving chicken erythrocytes coated with an anti-human-haemoglobin antibody. Hemoccult II and Hemoccult II Sensa are guaiac based tests. Claims 1-13 and 20-26 are considered to lack an inventive step in the light of this disclosure as it would be an obvious extension of the above findings to combine the two tests (a chromogen based test with an immunoassay based test) into a single test matrix.

Derwent Abstract Accession No 92-134663/17 discloses a two stage filter system for the identification of blood for early detection of intestinal cancer. The first stage uses the peroxidase reaction of haemoglobin which changes colour on a chemical impregnated filter paper (i.e. the well known guaiac based chromogen test for blood), the second step is based on an immuno-chemical reaction specific to human blood using anti-human haemoglobin and involves counter-immuno-electrophoresis. Claims 1-13 and 20-26 are considered to lack novelty in the light of this disclosure.

European Journal of Surgical Oncology (1989), 15, 446-448 discloses a combination guaiac and immunological test. The addition of the immunological part of the test is said to lead to an improvement in specificity and an increase in the predictive value of the test for colorectal cancer. The sample was absorbed on to a guaiac impregnated pad for one part of the test and also onto individual paper discs for use in the immunological part of the test. Claims 1-13 and 20-26 are considered to lack an inventive step in the light of the above disclosure because it would be an obvious extension of the findings of improved specificity and positive predictive value of the combined test results to simplify the combination test by incorporating the two tests into a single test matrix.

AU B 84188/82 (541099) (F. Hoffmann-La Roche and Co. Aktiengesellschaft) discloses a method for the detection of occult human blood in human stool samples according to the peroxidase method followed by immunologically detecting, in the same stool sample, a component of human origin (eg human haemoglobin (see page 4 line 3)) which is not normally present in human stool. Claim 1-13 and 20-26 are considered to lack novelty in the light of this disclosure. (continued)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/AU99/01014

VI. Certain documents cited**1. Certain published documents (Rule 70.10)**

Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
AU 77440/98	04/02/99	22/07/98	25/07/97

2. Non-written disclosures (Rule 70.9)

Kind of non-written disclosure	Date of non-written disclosure (day/month/year)	Date of written disclosure referring to non- written disclosure (day/month/year)

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The method defined by claims 27 and 28 is not fully supported by the description because step (ii) suggest that an analyte-anti-analyte complex is first formed between any analyte and an anti-analyte immunoreactive (or immunointeractive) molecule, this complex is subsequently immobilised and **the said complex** detected by contacting the analyte with an anti-analyte immunointeractive conjugate. In the examples the biological sample is first contacted with an anti-analyte immunointeractive **conjugate** (i.e. the labelled specific binding partner), the sample, including the complex formed between any analyte present and the anti-analyte immunointeractive **conjugate** is then contacted with an immobilised anti-analyte antibody (immobilised anti-analyte immunoreactive (or immunointeractive molecule).

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of V.2. Citations and explanations

CLIN. CHEM. (1988), 34 (9), 1763-1766 discloses a novel latex-agglutination based immunochemical test for the rapid detection of faecal occult blood. The immunochemical test (Hemolex) was shown to be insensitive to bleeding in the upper gastrointestinal tract, unlike the guaiac tests. Thus, Hemolex gave negative results when blood was ingested, whereas Fecatwin gave positive test results (page 1764 column 2). The Hemolex test was found to be more sensitive to bleeding in the lower intestinal canal than are guaiac-based tests (Hemoccult, Hemofec and Fecatwin Sensitive) and it has been shown to be suitable for screening for occult blood originating there. Thus, of 11 specimens from patients with verified bleeding from the upper GI tract the following number of positive results were produced by the specific test method used in the assay:- Hemolex (3), Hemofec (9), Hemoccult (10), Fecatwin (11), and of 15 specimens from patients with bleeding from the lower GI tract the following number of positive results were produced by the specific test method used in the assay:- Hemolex (14), Hemofec (5), Hemoccult (10), Fecatwin (12).

Claims 8-19 are considered to lack an inventive step since this disclosure gives clear indications that a combination of a chromogen based (guaiac based) test and an immunochemical based test for human haemoglobin may be used to distinguish between upper and lower gastrointestinal tract bleeding and it would be an obvious extension to incorporate the two tests into a single test matrix.

Am. J. Gastroenterol. (1999) February, 334 (2), 344-350 was published after the priority date of the claims and hence is not considered relevant to the questions of want of novelty or inventive step.

AU 23725/97 (Bayer Corp.) discloses an immunochromatographic test strip which is developed by applying the test fluid sample thereto, thereby allowing it to contact the mobile, labelled specific binding partner for the analyte. The fluid test sample carries the analyte/labelled binding partner conjugate and unreacted labelled binding partner along the strip to a second region (the detection zone) which, in the sandwich format, contains immobilised binding partners specific to a second epitope on the analyte for capture of the analyte/specific binding partner complex. The sensitivity of the determination can be enhanced by providing a strip with a third region which region contains means for immobilising the labelled specific binding partner species which did not bind in the detection zone (in the sandwich format, the labelled specific binding partner species which did not bind in the detection zone is the **uncomplexed labelled binding partner**) (see page 4 line 24 to page 6 line 4). Inaccuracies caused by uneven deposition of labelled conjugate and/or non-uniform fluid flow through the matrix can be corrected by measuring the signal from the detectable label immobilised in the third region and determining the ratio of the signal from labelled binding partner in the second region to that in the third region. Claims 27-29 and 31 are considered to lack novelty in the light of this disclosure.

EP 465266 (Sangstat Medical Corporation) discloses a device comprising a bibulous membrane comprising a plurality of distinct regions for the detection of analyte; each analyte detection region is used to perform either a sandwich-type or a competition-type immunoassay in which a visual signal is produced. For every analyte to be detected, the bibulous membrane comprises at least one pair of a sandwich-type and a competition-type analyte detection region. Claims 27-29 and 31 are considered to lack novelty in the light of this disclosure.

(continued)

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of V.2. Citations and explanations

WO 91/12528 (Hygeia Sciences, Inc.) discloses an immunoassay method using a multi-zoned test strip in which the sample is contacted with a water-dispersible labelled first immunologically reactive substance and a water-dispersible capturable second immunologically reactive substance and a detection zone comprising a capturing substance. (see page 4 line 8 to page 5 line 16). This disclosure together with the disclosure of any one of EP 465266, EP 724157, WO 97/35205 or WO 98/33069 is considered to render claims 27-28 (which specifically require the formation of a complex between the analyte and an anti-analyte immunointeractive (immunoreactive) molecule (not the anti-analyte immunointeractive conjugate) before immobilisation) as lacking an inventive step.

EP 724157 (Bayer Corp.) discloses an immunochromatographic test strip which comprises (i) a second region containing immobilised analyte, in which unreacted labelled binding partner is bound to the immobilised analyte in an inverse relationship to the concentration of the analyte and (ii) a third region which contains a means for immobilising the complex formed between the analyte and the labelled binding partner. The signal from the detectable label immobilised in the third region is measured and the ratio of the signal from the labelled binding partner immobilised in the second region and the immobilised complex in the third region is determined. Claims 27-29 and 31 are considered to lack novelty in the light of this disclosure.

WO 97/35205 (Serex, Inc.) discloses a device similar to that disclosed in EP 724157 above, in which an immobilised ligand which is essentially non-competitive with the analyte for the labelled binding partner (also referred to as the labelled receptor) is situated in the second region. Claims 27-29 and 31 are considered to lack novelty in the light of this disclosure.

WO 98/33069 (Smithkline Diagnostics, Inc.) discloses that proteins such as haemoglobin, frequently assayed in determinations of faecal occult blood is among the analytes frequently assayed with chromatographic assay systems (see for example page 32). This document discloses a chromatographic assay device having a detection zone containing an immobilised specific binding partner for the analyte and a sample preparation zone including a labelled specific binding partner for the analyte. The assay device can include a control zone which contains analyte immobilised thereto (see claims 6-7, 17-18, 29-30), which is used to bind labelled specific binding partner to verify that the assay has been performed properly (page 17 lines 30-33). Claims 27-29 and 31-34 are considered to lack novelty in the light of this disclosure.

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of IV. 2. Lack of unity of invention

The features common to the two groups of claims are :- (i) applying a biological sample to a first region of a test matrix, (ii) allowing the sample to flow to a second region of the test matrix where it is contacted with an anti-analyte-immunointeractive molecule, allowing any analyte present to form an analyte-anti-analyte immunointeractive complex, immobilising the complex and detecting this complex by contacting it with an anti-analyte-immunointeractive conjugate. These steps amount to nothing more than the standard steps involved in a typical sandwich immunoassay which are very well known in the art, examples of which are WO 96/28715, US 4960691, US 4943522 to name but a few.

The requirement of unity of invention (Rule 13.1) is fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression **special technical features** means those technical features that define a contribution which each of the claimed inventions makes over the prior art. As the method steps involving addition of a sample to a first region and allowing the sample to flow to a second region where the presence of an analyte is detected by means of an anti-analyte immunointeractive molecule amount to nothing more than a standard sandwich immunoassay one has to look to the use of a third region of the test matrix to determine any "special technical feature". The third region of the test matrix of claims 1-26 is used to detect the presence of haem (heme) using a chromogen base assay. The use of a chromogen to detect the presence of haem on a test strip is well known in the prior art and forms the basis of the currently available Hemocult II® and HemocultSENSA® guaiac-based tests. Likewise immunochemical tests for haemoglobin are also well known in the prior art, examples of which are HemeSelect® and HemoQuant®. The "special technical features" of claim 1-26 thus reside in the use of a combination of an immunoassay for globin and a chromogen based test for haem, for the detection of blood on a single test matrix, this being because both a chromogen based test for haem and an immunoassay for haemoglobin are both well known in the prior art, as mentioned above.

The "special technical features" of claims 27-34 relate to the detection of uncomplexed anti-analyte immunointeractive conjugate in a further separate region of a standard sandwich-type immunoassay.

These two inventions are not so linked as to form a single general inventive concept. There is no technical relationship among these two inventions involving one or more of the same or corresponding special technical features.

Further support for the above assertion of lack of unity of invention comes from the fact that a search conducted to establish the novelty and /or inventiveness of the invention defined by claims 1-26 **will not** establish the novelty and inventiveness of claims 27-34 and *vice versa*.

Additional evidence that the above two groups of claims define separate inventions and that one is not merely a broader form of the other can be found in the description, in particular example 4 (page 32) from which the following results have been extracted:-

For the invention defined by claim 1-26 (test involving capture Ab (anti-Hb) and Guaiac or similar chromogen for the detection of haem)

<u>Condition</u>	<u>Line 1</u> (anti-Hb)	<u>Line 4</u> (Guaiac)
no blood	-	-
lowerGI		
v.high[Hb]	-	+

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of IV. 2. Lack of unity of invention

For the invention defined by claims 27-34 (test involving capture Ab (anti-Hb) and anti-conjugate (Hb))

<u>Condition</u>	<u>Line 1</u> (anti-Hb)	<u>Line 3</u> (Hb)
no blood	-	+
lower GI		
v.high[Hb]	-	-

From these results it can be clearly seen that the two inventions measure quite different species and hence give quite different results i.e. one invention is not merely a broader form of the other invention.

Claims 35-39 are considered to possess unity of invention with each of the above two groups of claims.